Denali Therapeutics (NASDAQ:DNLI) Given New $41.00 Price Target at Stifel Nicolaus

Denali Therapeutics (NASDAQ:DNLI) had its price target upped by analysts at Stifel Nicolaus from $34.00 to $41.00 in a report released on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price indicates a potential upside of 97.07% from the company’s previous close.

A number of other research analysts have also weighed in on the stock. Morgan Stanley reissued an “overweight” rating and set a $40.00 price target on shares of Denali Therapeutics in a research report on Thursday, January 8th. Robert W. Baird lifted their target price on shares of Denali Therapeutics from $29.00 to $32.00 and gave the stock an “outperform” rating in a research report on Thursday. HC Wainwright boosted their price objective on Denali Therapeutics from $32.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday. Jefferies Financial Group reaffirmed a “buy” rating and set a $40.00 target price on shares of Denali Therapeutics in a research report on Monday, March 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.10.

Denali Therapeutics Stock Down 7.4%

NASDAQ DNLI traded down $1.67 on Thursday, reaching $20.81. The company had a trading volume of 589,104 shares, compared to its average volume of 1,721,014. The stock has a market capitalization of $3.30 billion, a P/E ratio of -7.00 and a beta of 1.02. The company’s fifty day moving average is $20.41 and its 200 day moving average is $17.80. Denali Therapeutics has a 52-week low of $10.57 and a 52-week high of $23.77. The company has a quick ratio of 9.16, a current ratio of 9.16 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.02. During the same quarter in the previous year, the company earned ($0.67) EPS. Sell-side analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, insider Alexander O. Schuth sold 17,218 shares of the company’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $284,097.00. Following the sale, the insider directly owned 282,828 shares of the company’s stock, valued at $4,666,662. This represents a 5.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Ryan J. Watts sold 35,198 shares of Denali Therapeutics stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $580,767.00. Following the completion of the transaction, the chief executive officer owned 296,833 shares of the company’s stock, valued at $4,897,744.50. The trade was a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

Several institutional investors have recently made changes to their positions in the stock. State of Wyoming boosted its holdings in shares of Denali Therapeutics by 24.7% in the fourth quarter. State of Wyoming now owns 2,686 shares of the company’s stock worth $44,000 after acquiring an additional 532 shares during the period. Intrust Bank NA raised its stake in shares of Denali Therapeutics by 5.6% during the 4th quarter. Intrust Bank NA now owns 11,164 shares of the company’s stock valued at $184,000 after purchasing an additional 589 shares during the period. ADAR1 Capital Management LLC lifted its holdings in Denali Therapeutics by 1.2% during the 4th quarter. ADAR1 Capital Management LLC now owns 52,116 shares of the company’s stock worth $860,000 after purchasing an additional 600 shares in the last quarter. Pier 88 Investment Partners LLC lifted its holdings in Denali Therapeutics by 1.1% during the 4th quarter. Pier 88 Investment Partners LLC now owns 68,200 shares of the company’s stock worth $1,126,000 after purchasing an additional 760 shares in the last quarter. Finally, Tudor Investment Corp ET AL boosted its stake in Denali Therapeutics by 1.7% in the 3rd quarter. Tudor Investment Corp ET AL now owns 56,368 shares of the company’s stock worth $818,000 after purchasing an additional 920 shares during the period. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Key Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA grants accelerated approval to AVLAYAH, the first brain‑penetrant enzyme replacement therapy for Hunter syndrome — validates Denali’s TransportVehicle™ platform, creates a near‑term commercial product, and comes with a Rare Pediatric Disease Priority Review Voucher that can be monetized or used for future filings. GlobeNewswire: FDA approval press release
• Positive Sentiment: Multiple analyst price‑target raises and bullish ratings today (BTIG to $38 buy, HC Wainwright to $42 buy, Robert W. Baird to $32 outperform) — these raise consensus upside and can attract institutional buying. Benzinga: analyst coverage roundup
• Positive Sentiment: Denali is hosting a conference call/webcast to discuss FDA approval and launch plans — investors will be watching commercialization timelines, pricing, supply and patient‑support programs for early revenue signals. Seeking Alpha: approval and launch transcript
• Neutral Sentiment: Regulatory designation context — approval was granted on a biomarker (CSF heparan sulfate) as a surrogate endpoint under accelerated approval; this speeds commercialization but leaves confirmatory evidence required. GlobeNewswire: approval details
• Neutral Sentiment: Short‑interest reporting in public feeds appears inconsistent/erroneous (entries showing 0 shares / NaN); current short data is not meaningful for interpreting immediate pressure. (Multiple short‑interest entries)
• Negative Sentiment: Continued approval is contingent on confirmatory Phase 2/3 COMPASS results — failure or delay in that trial could materially hurt valuation and limit label permanence. GlobeNewswire: confirmatory trial notes
• Negative Sentiment: Safety and use limitations — infusion‑related reactions, anaphylaxis risk, reports of anemia and rare kidney issues, and the label’s restriction against combining with other ERTs may limit uptake and complicate reimbursement. GlobeNewswire: safety and limitations
• Negative Sentiment: Recent insider sales and reported institutional rebalancing (Quiver/Globe reporting) could add near‑term supply pressure on the stock as holders take profits after the run‑up. QuiverQuant: insider & institutional activity

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.